A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.
5 affiliations
- 1Department of Medicine, Division of Gastroenterology, University of Toronto, Toronto, ON, Canada.
- 2Health Economics and Government Relations, Johnson & Johnson Canada Inc., Toronto, ON, Canada.
- 3Medical Affairs, Johnson & Johnson Canada Inc., Toronto, ON, Canada.
- 4Real World Solutions, IQVIA Solutions Canada, Inc., Kirkland, QC, Canada.
- 5Department of Medicine, Division of Gastroenterology, McMaster University, Hamilton, ON, Canada.
Abstract
Background
Inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), are increasingly prevalent. Ustekinumab (UST), a biologic therapy, has shown efficacy in treating CD and UC, but its real-world impact is less clear. This study assessed all-cause and IBD-specific healthcare resource utilization (HCRU) and costs, excluding medication costs, among patients with CD and UC initiated on UST.Methods
This retrospective cohort study in Ontario, Canada included patients initiating UST between January 2017 and September 2022. Patients were identified through the Johnson & Johnson (J&J) BIOADVANCE® patient support program and deterministically linked to ICES databases. Outcomes were compared between 1 year pre-initiation of therapy and each post-initiation year (up to 4 years). Results were reported for patients who were persistent on UST at each year of the analysis period, patients who were persistent vs. discontinued UST for the duration of Year 1, and patients who were biologic-naïve versus bio-experienced prior to index.Results
The study cohort included 2279 patients with CD and 626 patients with UC. UST initiation was associated with significant reductions (P < .001) in the number of all-cause HCRU events in each year of follow-up, including for CD patients who were biologic-naïve and persistent on UST. Non-medication costs were lower for both CD and UC patients in all years, and significant in Years 1-3 for CD and Year 2 for UC patients.Conclusions
In CD and UC patients, all-cause and IBD-specific HCRU and non-medication healthcare costs were lower in years following UST initiation.
Related
- Nutritional status, clinical burden, and healthcare utilization among pediatric outpatients with congenital heart disease: A retrospective cross-sectional study from Indonesia
- Determinants of the continuum of maternal healthcare service utilization in Nigeria: Evidence from the 2024 Nigeria Demographic and Health Survey
- Co-exposure to planned power outages and wildfire PM2.5 and acute healthcare utilization in California: A time-stratified case-crossover study
- Ustekinumab for Extraintestinal Manifestations in Patients With Inflammatory Bowel Disease: Lessons From the TENOR Real-World Study.
- Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
BibTeX
@article{targownik2026realworld,
title = {{A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.}},
author = {Laura Targownik and Eneda Pone and Martin G Latour and Kasra Boyerahmadi and Huijuan Yang and Juejing Ling and Ali Tehrani and Shane Golden and John K Marshall},
journal = {Crohn's \& colitis 360},
year = {2026},
month = oct,
doi = {10.1093/crocol/otag103},
url = {https://europepmc.org/article/MED/42910390},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - A real-world study of healthcare resource utilization and costs in patients with Crohn's disease and ulcerative colitis initiating ustekinumab treatment via Johnson & Johnson's BIOADVANCE program.
AU - Laura Targownik
AU - Eneda Pone
AU - Martin G Latour
AU - Kasra Boyerahmadi
AU - Huijuan Yang
AU - Juejing Ling
AU - Ali Tehrani
AU - Shane Golden
AU - John K Marshall
PY - 2026
DA - 2026/10/19
JO - Crohn's & colitis 360
DO - 10.1093/crocol/otag103
UR - https://europepmc.org/article/MED/42910390
AB - Background Inflammatory bowel diseases (IBDs), including Crohn's disease (CD) and ulcerative colitis (UC), are increasingly prevalent. Ustekinumab (UST), a biologic therapy, has shown efficacy in treating CD and UC, but its real-world impact is less clear. This study assessed all-cause and IBD-specific healthcare resource utilization (HCRU) and costs, excluding medication costs, among patients with CD and UC initiated on UST.Methods This retrospective cohort study in Ontario, Canada included patients initiating UST between January 2017 and September 2022. Patients were identified through the Johnson & Johnson (J&J) BIOADVANCE® patient support program and deterministically linked to ICES databases. Outcomes were compared between 1 year pre-initiation of therapy and each post-initiation year (up to 4 years). Results were reported for patients who were persistent on UST at each year of the analysis period, patients who were persistent vs. discontinued UST for the duration of Year 1, and patients who were biologic-naïve versus bio-experienced prior to index.Results The study cohort included 2279 patients with CD and 626 patients with UC. UST initiation was associated with significant reductions (P < .001) in the number of all-cause HCRU events in each year of follow-up, including for CD patients who were biologic-naïve and persistent on UST. Non-medication costs were lower for both CD and UC patients in all years, and significant in Years 1-3 for CD and Year 2 for UC patients.Conclusions In CD and UC patients, all-cause and IBD-specific HCRU and non-medication healthcare costs were lower in years following UST initiation.
SN - 2631-827X
ER -